Urapidil
As of the edition of 20 October 2026, Urapidil is a small molecule: marketed, first approved in 1983 (CH); acts on ADRA1A, ADRA1B and ADRA1D.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1988
- Kind
- Small molecule
- Brand name
- Ebrantil
- First approved
- 21 July 1983 (CH)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- CHEPLAPHARM ARZNEIMITTEL (ALLEMAGNE); 2 holders in all
- Registered trials
- 8, 2 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Mental health; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 2 | 1 | 1 |
| Phase 1 | 1 | 0 | 0 | 0 |
| Phase 3 | 2 | 1 | 0 | 1 |
| All trials | 8 |